A phase II study of gemcitabine and erlotinib as adjuvant therapy in patients with resected pancreatic cancer.
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2016
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Jan 2012 Actual patient number (28) added as reported by ClinicalTrials.gov.
- 06 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.